$-0.19 EPS Expected for Affimed N.V. (AFMD)

March 14, 2018 - By Adrian Mccoy

 $ 0.19 EPS Expected for Affimed N.V. (AFMD)

Analysts expect Affimed N.V. (NASDAQ:AFMD) to report $-0.19 EPS on March, 29.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.21 EPS previously, Affimed N.V.’s analysts see -9.52 % EPS growth. It closed at $2.2 lastly. It is down 19.09% since March 15, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Leerink Swann given on Thursday, May 19. The stock of Affimed N.V. (NASDAQ:AFMD) has “Buy” rating given on Thursday, December 10 by Laidlaw. The stock of Affimed N.V. (NASDAQ:AFMD) earned “Hold” rating by Jefferies on Monday, June 12. The company was initiated on Tuesday, April 12 by BMO Capital Markets. Zacks upgraded the stock to “Sell” rating in Monday, August 10 report. Jefferies initiated it with “Hold” rating and $11 target in Wednesday, September 9 report. The stock of Affimed N.V. (NASDAQ:AFMD) has “Market Perform” rating given on Friday, August 12 by Leerink Swann. Zacks upgraded Affimed N.V. (NASDAQ:AFMD) on Thursday, September 3 to “Hold” rating. The firm has “Outperform” rating given on Thursday, August 6 by Oppenheimer. Jefferies maintained it with “Hold” rating and $2.5 target in Thursday, August 31 report.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $133.46 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More important recent Affimed N.V. (NASDAQ:AFMD) news were published by: Prnewswire.com which released: “What’s Happening with These Biotech Stocks? — Aeterna Zentaris, Affimed …” on March 13, 2018, also Globenewswire.com published article titled: “Affimed Announces Fourth Quarter and Year End 2017 Financial Results and …”, Nasdaq.com published: “Affimed to Present at the Cowen and Company 38th Annual Health Care Conference” on March 08, 2018. More interesting news about Affimed N.V. (NASDAQ:AFMD) was released by: Globenewswire.com and their article: “Affimed Announces Pricing of Public Offering of Common Stock” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.